TP53 and acute myeloid leukemia: The addition of mevalonate to simvastatin-containing co-incubation assays completely restored the TP53 deficiency-associated resistance of AML cells to CAR T-cell killing with no effect on killing of MOLM13-TP53+/+ AML cells (Fig. 5B,C and EV4E).